Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study

Supportive Care in Cancer

Volumn 24, Issue 8, 2016, Pages 3369-3377

  Mahe I ^a,b   Puget, H ^a   Buzzi, J C ^c   Lamuraglia, M ^a   Chidiac, J ^a   Strukov, A ^c   Helfer, Hélène ^a   Perozziello, A ^c  

^a HÔPITAL LOUIS MOURIER   (France)

^b Lariboisière Hospital   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Cancer; Low molecular weight heparin; Practice; Standard; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; TINZAPARIN; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ARTICLE; CANCER ASSOCIATED THROMBOSIS; CATHETER THROMBOSIS; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; VENOUS THROMBOEMBOLISM; COMPLICATION; HOSPITALIZATION; NEOPLASM; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA;

AGED; ANTICOAGULANTS; COHORT STUDIES; FEMALE; GUIDELINE ADHERENCE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 84961198226     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3164-8     Document Type: Article

References (19)

1. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464
2. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk Analysis Using Medicare Claims Data Medicine (Baltimore) 78:285–291
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634
4. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D’Angelo A, Pengo V, Moia M, Coccheri S (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805–810
5. Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Levesque H, Renaudin JM, Farge D (2009) Working group of the SOR, French National Federation of Cancer C. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 20:1459–1471
6. Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quere I, Levesque H, Debourdeau P (2010) 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 73:31–46
7. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, et al. (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11:56–70
8. Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, Schrag D (2012) Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist 17:419–427
9. Spirk D, Ugi J, Korte W, Husmann M, Hayoz D, Baldi T, Frauchiger B, Banyai M, Aujesky D, Baumgartner I, Kucher N (2011) Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II. Thromb Haemost 105:962–967
10. Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, Lopez-Jimenez L, Garcia-Bragado F, Quintavalla R, Monreal M, Investigators R (2010) Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 125(Suppl 2):S58–S61
11. Belhadj Chaidi R, Thollot C, Ferru A, Roblot P, Landron C (2013) Adherence to guidelines for the treatment of venous thromboembolism in cancer patients: a retrospective analysis of 145 cases. J Mal Vasc 38:185–192
12. Sevestre MA, Belizna C, Durant C, Bosson JL, Vedrine L, Cajfinger F, Debourdeau P, Farge D (2014) Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 39:161–168
13. Farge D, Gorin NC, Debourdeau P, Lamblin A, Cajfinger F (2014) Long-term use of low-molecular-weight heparin (LMWH) for cancer associated venous thromboembolism (VTE): adherence to recommendations in clinical practice based on tropique, a prospective observational study. Blood Coagul Fibrinolysis: Int J Haemost Thromb 124(21):1545
14. AFSOS 2013 Prise en charge de la maladie thromboembolique veineuse en cancérologie. Référentiels de l’Association Francophone pour les Soins Oncologiques de Support wwwafsosorg
15. Sousou T, Khorana A (2009) Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 29:121–124
16. Cimminiello C, Anderson FA Jr (2012) Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey. Thromb Res 129:139–145
17. Seaman S, Nelson A, Noble S (2014) Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 8:453–461
18. Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schunemann H (2014) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 7:CD006650
19. Heit JA (2005) Cancer and venous thromboembolism: scope of the problem. Cancer Control: J Moffitt Cancer Center 12(Suppl 1):5–10